Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison
ConditionBrain Neoplasms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRegion Stockholm
About this trial
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years or older
Scheduled for clinical brain MRI with gadolinium contrast
Known or suspected brain metastases
Able to provide informed consent
Disqualifiers
Contraindications to MRI
Known allergy or contraindication to gadolinium-based contrast agents
Renal impairment (eGFR < 30 mL/min/1.73m²)
Pregnant or breastfeeding
Trial population
Patients referred for clinical brain MRI with contrast at a university hospital radiology department in Sweden. Participants will be adults with known or suspected brain metastases undergoing routine post-gadolinium imaging as part of their diagnostic work-up.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Novel Gadolinium-Weighted MRI Sequence
Diagnostic testA post-contrast MRI sequence incorporating magnetization transfer (MT) preparation and flow-nulling with motion-sensitized driven equilibrium (MSDE). The sequence is optimized to suppress background tissue and vascular signal while enhancing the visibility of gadolinium-enhancing brain metastases. It is compared to conventional T1-weighted imaging in the same exam session.
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Patients with Suspected or Known Brain Metastases1 intervention
Trial outcomes
Primary outcomes
1
Difference in Number of Detected Gadolinium-Enhancing Brain Metastases Between the Novel Gadolinium-Weighted MRI Sequence and Conventional T1-Weighted Imaging
Time frame
At the time of gadolinium-enhanced MRI, during a single imaging session (within 1 hour of contrast administration)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov